Biostar Pharmaceuticals, Inc. (BSPM) Is At $1.94 Formed Wedge; GNC Holdings Has 0.61 Sentiment

Biostar Pharmaceuticals, Inc. (BSPM) formed wedge up with $2.08 target or 7.00% above today’s $1.94 share price. Biostar Pharmaceuticals, Inc. (BSPM) has $5.12 million valuation. It closed at $1.94 lastly. It is down 57.27% since December 26, 2016 and is uptrending. It has outperformed by 40.57% the S&P500.

GNC Holdings, Inc., together with its subsidiaries, operates as a specialty retailer of health, wellness, and performance products. The company has market cap of $256.69 million. The Company’s products include protein, performance supplements, weight management supplements, vitamins, herbs and greens, wellness supplements, health and beauty, food and drink, and other general merchandise. It currently has negative earnings. The firm sells its products under the GNC proprietary brands, as well as under third-party brands.

Sterneck Capital Management Llc holds 0.88% of its portfolio in GNC Holdings, Inc. for 173,350 shares. Sessa Capital Im L.P. owns 500,000 shares or 0.49% of their US portfolio. Moreover, Blue Ridge Capital L.L.C. has 0.38% invested in the company for 2.41 million shares. The United Kingdom-based Impax Asset Management Ltd has invested 0.33% in the stock. Quinn Opportunity Partners Llc, a New York-based fund reported 164,564 shares.

Since January 1, 0001, it had 0 buys, and 1 sale for $599,070 activity.

Ratings analysis reveals 0 of GNC Holdings’s analysts are positive. Out of 5 Wall Street analysts rating GNC Holdings, 0 give it “Buy”, 3 “Sell” rating, while 2 recommend “Hold”. The lowest target is $16.0 while the high is $21.0. The stock’s average target of $18.50 is 397.31% above today’s ($3.72) share price. GNC was included in 5 notes of analysts from September 23, 2016. The stock has “Equal Weight” rating by Barclays Capital on Friday, September 23. Bank of America downgraded the shares of GNC in report on Friday, October 28 to “Underperform” rating. The rating was downgraded by Piper Jaffray on Friday, October 28 to “Underweight”. Goldman Sachs downgraded the stock to “Sell” rating in Thursday, January 19 report. Deutsche Bank maintained the stock with “Hold” rating in Friday, October 28 report.